Oxidative And Nitrosative Modulators In Neuroinflammation

More documents

Recommendations

Info

OXIDATIVEANDNITROSATIVEMODULATORSINNEUROINFLAMMATION ofsupranuclearhyperintensesignalsseenontheT2sequencewasstatisticalysignificantlyhigherinthe RRMSgroupofpatients(medianvalueforthetotalnumberoflesionsandthenumberofsupratentorallo- numberofsupratentorallesions-8(0-80),p=0.023ip=0.03.ThevolumeofGdbindinglesionsseenon theT1sequencewasstatisticalysignificantlyhigherintheRRMSgroup,bothinthebrain(277.7±109.1 mm3)andinthebiomass(641.3±210.2.1mm3),incomparisonwiththesamefindinginthebrain(146.5± 46.8mm3)andcysticmoss(446.6±120.1mm3)ofpatientsintheKISgroup,p=0.031(forthebrain),p= 0.04. -Concentrationsofexaminedparametersinrelationtopatientage:Itwasfoundthatolderpatientshad calizationlesions-40(5-84supratentoral,3-70infratentionallocalization)comparedtothesamecharac- teristicsinKISpatients(medianvalueforthetotalnumberoflesions-9(0-56),medianvalueforthetotal higherconcentrationsofNO2andNO3comparedtoyoungerpatients,andinKIS(plasma-p=0.034,cerebrospinalfluid-p=0.04),andintheRRMSgroup(plasma-p=0.03;cerebrospinalfluid-p=0.025).Simi- larly,theconcentrationofMDAinalinvestigatedmediawashigherintheelderlygroupcomparedto youngerpatients,inbothexaminedgroups,KIS(plasma-p=0.07;cerebrospinalfluid-p=0.06;hemolysate-p=0.09),andintheRRMSgroup(plasma-p=0.055;cerebrospinalfluid-p=0.065;hemolysate-p= 0.06).AOPPconcentrationsincreasedinthegroupofelderlypatientsandinKIS(plasma-p=0.05;cerebro- observedinelderlypatientscomparedtoyoungerandKIS(plasma-p=0.025,cerebrospinalfluid-p=0.04, inKIS(plasma-p=0.065;cerebrospinalfluid-p=0.031;haemolysate-p=0.05)andinRRMSpatients (plasma-p=0.025;-p=0.07). -Concentrationsofexaminedparametersinrelationtohalfofpatients:Analysisoftheobtainedvaluesof thetestedparameters,comparedtohalfofpatients,itwasfoundthatmenhavehighervaluesofNO2and NO3concentrationsinrelationtowomen,andinKIS(plasma-p=0,06,cerebrospinalfluid-p=0,075),and spinalfluid-p=0.06;hemolysate-p=0.055),andintheRRMSgroup(plasma-p=0.06;=0.04;hemolysate-p=0.095).Atthesametime,thedecreaseinSHvaluesinplasmaandliver,GSHinhemolysateswas hemolysate-p=0.9)andinRRMSpatients(plasma-p=0.015;cerebrospinalfluid-p=0.035;hemolysatep=0.75).ThetrendofdeclineintheactivityofSODwiththeincreaseintheyearsoflifewasalsoobserved intheRRMSgroup(plasma-p=0,065;cerebrospinalfluid-p=0,023).TheconcentrationofMDAinalinvestigatedmediawasselectivelyhigherinwomencomparedtomen,inbothexaminedgroups,KIS(plasma -p=0.078,cerebrospinalfluid-p=0.045,hemolysate-p=0.9),andintheRRMSgroup(plasma-p=0.85; cerebrospinalfluid-p=0.95;hemolysate-p=0.6).
OXIDATIVEANDNITROSATIVEMODULATORSINNEUROINFLAMMATION ConcentrationsofAOPPshowedanincreaseinconcentrationinmenversuswomenandinKIS(plasma-p= 0.58,cerebrospinalfluid-p=0.6;haemolysate-p=0.55),andinRRMSpatients(plasma-p=0,06; cerebrospinalfluid-p=0.06;hemolysate-p=0.55).ThedecreaseinthevalueofSHgroupsinplasmaand liver,ieGSHinhemolysates,inwomenversusmenandinKIS(plasma-p=0.095;cerebrospinalfluid-p= 0.055;hemolysate-p=0.65)andRRMSpatients(plasma-p=0.025;cerebrospinalfluid-p=0.025; hemolysate-p=0.07).ThedeclineinSODactivitywasmoredominantinwomencomparedtomenandin KIS(plasma-p=0.075,cerebrospinalfluid-p=0.3;hemolysate-p=0.05)andinRRMSpatients(plasmap=0.065;=0.03;hemolysate-p=0.045). REFERENCES Polman,C.H.,Reingold,S.C.,Banwel,B.,Clanet,M.,Cohen,J.A.,Filippi,M.,Fujihara,K.,Havrdova,E.,Hutchinson,M., Kappos,L.,Lublin,F.D.,Montalban,X.,O'Connor,P.,Sandberg-Wolheim,M.,Thompson,A.J.,Waubant,E.,Weinshenker, B.,Wolinsky,J.S.(2011).Diagnosticcriteriaformultiplesclerosis:2010RevisionstotheMcDonaldcriteria.Ann. Neurol.69(2),292-302. Lublin,F.D.,Reingold,S.C.(1996).Definingtheclinicalcourseofmultiplesclerosis:resultsofaninternationalsurvey. NationalMultipleSclerosisSociety(USA)AdvisoryCommiteeonClinicalTrialsofNewAgentsinMultipleSclerosis. Neurology46,907-11. Kurtzke,Ј.F.(1983)Ratingneurologicimpairmentinmultiplesclerosis:Anexpandeddisabilitystatusscale(EDSS). Neurology33,1444–52. Navaro-Gonzalvez,J.A.,Garcia-Benayas,C.,Arenas,J.(1998).Semiautomatedmeasurementofnitrateinbiological fluids.Clin.Chem.44,679-81. <strong>And</strong>reeva,L.I.,Kozhemiakin,L.A.,Kishkun,A.A.(1988).Modificationofthemethodofdetermininglipidperoxidation inatestusingthiobarbituricacid.Laboratornoedelo,11,41-3. Witko-Sarsat,V.,Friedlander,M.,Capeilere-Blandin,C.,Nguyen-Khoa,T.,Nguyen,A.T.,Zingraf,J.,Jungers,P., DescampsLatscha,B.(1996).Advancedoxidationproteinproductsasanovelmarkerofoxidativestressinuremia. Kidney<strong>In</strong>t.49,1304-13. Sedlak,J.,Lindsday,R.(1968).Estimationoftotalproteinboundandnon-proteinsulphydrylgroupsintissuewith Elman’sreagent.AnalBiochem,25,192-2. Minami,M.,Yoshikawa,H.(1979).Asimplifiedassaymethodofsuperoxidedismutaseactivityforclinicaluse.Clin. Chim.Acta,92,337-42.
Page 1 and 2: OXIDATIVEANDNITROSATIVE MODULATORSI
Page 3 and 4: OXIDATIVEANDNITROSATIVEMODULATORSIN
Page 5 and 6: OXIDATIVEANDNITROSATIVEMODULATORSIN
Page 7: OXIDATIVEANDNITROSATIVEMODULATORSIN

Oxidative And Nitrosative Modulators In Neuroinflammation

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?